Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) EPS (Basic) (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed EPS (Basic) for 15 consecutive years, with -$0.11 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 47.62% to -$0.11 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.69 through Dec 2025, up 26.6% year-over-year, with the annual reading at -$0.69 for FY2025, 27.37% up from the prior year.
  • EPS (Basic) hit -$0.11 in Q4 2025 for Cardiff Oncology, up from -$0.17 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.11 in Q4 2025 to a low of -$0.26 in Q2 2024.
  • Historically, EPS (Basic) has averaged -$0.21 across 5 years, with a median of -$0.21 in 2025.
  • Biggest YoY gain for EPS (Basic) was 66.67% in 2021; the steepest drop was 200.0% in 2021.
  • Year by year, EPS (Basic) stood at -$0.24 in 2021, then grew by 16.67% to -$0.2 in 2022, then decreased by 5.0% to -$0.21 in 2023, then rose by 0.0% to -$0.21 in 2024, then surged by 47.62% to -$0.11 in 2025.
  • Business Quant data shows EPS (Basic) for CRDF at -$0.11 in Q4 2025, -$0.17 in Q3 2025, and -$0.21 in Q2 2025.